News and Announcements
EG Private Wealth sold a $26M industrial site, secured strong return for investors in excess of 27% p.a.
- Published September 08, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
EG has sold an industrial site at 22 Narabang Way, Belrose for $26 million, realising returns for our Private Wealth investors in excess of 27% p.a. over a 2.5-year hold period.
Acquired in January 2020 for $18.09 million, the modern, multi-let industrial facility is located in the tightly held and land-constrained Sydney Northern Beaches industrial market. It marks the first divestment of an EG Private Wealth syndicate, which has assembled a portfolio of nearly $200 million since launching in 2020.
“Securing this strong return for our investors is an example of what’s possible when data-driven investing strategies meet comprehensive market risk assessment. The high demand for industrial assets and the ability of EG’s team to execute our asset strategy by enhancing rents and improving the average lease expiry encouraged us to bring the property to market earlier than expected, exchanging in May 2022,” said EG’s Head of Private Wealth, Rodney Walt.
The property sits on a substantial 15,800sqm landholding and is located 23.5km north of the Sydney CBD. The anchor tenant, Fantastic Furniture, signed a lease in March 2020 and moved in 1 day after the property became vacant, highlighting EG’s leasing insights and deep understanding of the market.
The deal was brokered on-market by Gavin Bishop and Sean Thomson from Colliers International and Vincent West and Oliver Rosati from Upstate Commercial.
EG grows the wealth of its private investors through commercial property syndication opportunities. With capital security and stable income cashflows, EG takes a personalised and aligned approach to every opportunity.
Founded in 2000, EG has $5.1 billion under management on behalf of super funds and private wealth clients to generate outstanding returns with lasting social impact. With $3.9 billion in the development pipeline, and 16.7% per annum in realised IRR for institutional funds, EG is committed to finding a better path to better returns.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
